2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
04:00 p.m. - 05:30 p.m.
MCCNO - 265-268
Treatment Considerations, Drug Development, Therapy Sequence, Biological Therapies, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Adverse Events, Biological Processes, Molecular Biology, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, ALL, Non-Hodgkin Lymphoma, Research, Clinical Research, Clinical Trials, Real-World Evidence, Study Population, Human, Adult
PAPER

378 SWOG S1905: A phase 1/ 2 trial of OBI-3424 in relapsed/ refractory T-acute lymphoblastic leukemia

Anjali Sunder Advani, MD, Anna Moseley, MS2, Nikolaos Papadantonakis, MD, PhD, MSc3, Cecilia CS Yeung, MD, Professor Pathology4, Ryan Summers, MD5, Megan Othus, PhD6, Ryan D. Cassaday, MD7, Min Fang, MD, PhD, FACMG8, Ibrahim Aldoss, MD9, Kristen O'Dwyer, MD10, Keri Renee Maher, DO11, Emily Curran, MD12, Deepa Bhojwani, MD13, Susan Rheingold, MD14, Susan O'Brien, MD15, Jerald Radich, MD16, Brent Wood, MD, PhD17, David T. Teachey, MD18, Harry Erba, MD, PhD19
1 Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, United States
2 Fred Hutchinson Cancer Center, SWOG Statistical Data Management Center, Seattle, Washington, United States
3 Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
4 Fred Hutchinson Cancer Center, Translational Science and Therapeutics Division; University of Washington, Dept of Laboratory Medicine and Pathology, Seattle, Washington, United States
5 Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta; Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, United States
6 Fred Hutchinson Cancer Center, SWOG Statistical Data Management Center, Seattle, Washington, United States
7 Fred Hutchinson Cancer Center, University of Washington School of Medicine, Seattle, Washington, United States
8 Fred Hutchinson Cancer Center, Translational Science and Therapeutics Division; University of Washington, Dept of Laboratory Medicine and Pathology, Seattle, Washington, United States
9 City of Hope, Duarte, California, United States
10 University of Rochester School of Medicine and Dentistry, Rochester, New York, United States
11 Virginia Commonwealth University, Massey Comprehensive Cancer Center, Richmond, Virginia, United States
12 University of Cincinnati Cancer Center, Cincinnatu, Ohio, United States
13 Children's Hospital of Los Angeles; University of Southern California, Los Angeles, United States
14 Children's Hospital of Pennsylvania, Philadelphia, Pennsylvania, United States
15 University of California, Irvine; Chao Comprehensive Cancer Center, irvine, United States
16 Fred Hutchinson Cancer Center, Seattle, Washington, United States
17 Children's Hospital of Los Angeles, University of Southern California, Los Angeles, United States
18 The Children’s Hospital of Philadelphia and University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, United States
19 Duke University Comprehensive Cancer Center, Durham, North Carolina, United States

Background: Patients with relapsed/refractory (R/R) T- cell acute lymphoblastic leukemia (T-ALL) have dismal outcomes. The Aldo-keto reductase family 1 member C3 (AKR1C3) enzyme is highly expressed in T-ALL blasts. OBI-3424 is an investigational nitrogen mustard prodrug that is converted by AKR1C3 into a bis-alkyl agent capable of forming DNA crosslinks resulting in cell death. OBI-3424 has demonstrated efficacy in T-ALL preclinical models as monotherapy or in combination with nelarabine.

Objectives: S1905 assessed: (1) the safety and maximum tolerated dose (MTD) of OBI-3424 monotherapy; (2) response rates of OBI-3424 treated patients at the MTD; (3) AKR1C3 expression levels in study participants.

Methods: This trial was conducted through the NCTN from August 2020 through February 2026. Enrolled patients were at least 12 years old, with R/R T-ALL (>5% blasts in the bone marrow or blood), no evidence of central nervous system (CNS) disease, and adequate organ function.  Cytogenetic risk was classified according to the Groupe Francophone de Cytogenetique Hematologique (GFCH) 2023.

Treatment: OBI-3424 was dose escalated through 3 dose levels (DLs): DL1 (8 mg/m2), DL2 (10 mg/m2), DL3 (12 mg/m2) and administered on day 1 and 8 of each 21-day cycle. CNS prophylaxis included intrathecal chemotherapy.

Statistics: The Phase 1 portion used a 3+3 design, and the Phase 2 portion had a 3-stage design. Patients treated at the MTD in Phase 1 were included in the Phase 2 response assessment. Response was assessed within the first 4 cycles. The study was powered based on a null hypothesis response rate (CR/CRi) of 15% and alternative hypothesis response rate of 35% (one-sided type 1 error rate of 6% and 89% power).

Translational medicine studies: Flow cytometry measurable residual disease (MRD) testing was performed centrally. AKR1C3 expression was assessed by immunohistochemistry (IHC) and quantitative multiplex IHC in marrow, and RQ-PCR in blood.

Results: Twenty patients were evaluable (14 with relapsed disease; 6 with refractory disease); median age was 44 years (range 20-77). 70% were males and 45% self-identified as White; 15% Black; 5% Asian; 10% Pacific Islander; 25% Unknown. Median WBC at time of registration was 2.3 x 103/uL (range 0.1-71.8). Median bone marrow blast percentage was 80% (range 8-94). Risk stratification based on available cytogenetic and mutation data was: 3/20 (15%) favorable, 7/20 (35%) unfavorable, 6/20 (30%) standard or undetermined, and 4/20 (20%) with data unavailable; 30% of patients had ETP immunophenotype. Median salvage line of treatments was 2 (range 1-5); median number of relapses was 1 (range 1-3). 20% of patients had undergone a prior allogeneic transplant, and 95% of patients had received nelarabine. Baseline AKR1C3 expression by IHC was absent in 10% of patients, equivocal/ limited samples (30%), positive (55%), with data missing for 1 patient. The median percentage of dual positive CD3/AKR1C3 cells by IHC was 40% (range 1-80).

In Phase 1, 15 patients were evaluable with only 1 DLT noted at DL3: Gr 4 platelet count decrease deemed probably related to OBI-3424 (in a bone marrow with < 5% blasts lasting > 35 days beyond the last dose of OBI-3424). The MTD of OBI-3424 was determined to be 12 mg/m2. In 12 patients treated at MTD (including 7 treated at MTD during Phase 1), none achieved CR/CRi, and the study did not meet its efficacy endpoint. For the entire cohort, 1 patient achieved CRi, 1 PR, and 1 stable disease. Dual expression of CD3/ AKR1C3 by IHC staining was 44% and 80% in the patients achieving CRi and PR, respectively. Median number of cycles received was 1 (range 1-4). The most common adverse events were cytopenias, febrile neutropenia, and sepsis.

Summary: OBI-3424 was safe and tolerable in patients with R/R T-ALL. Despite most patients expressing AKR1C3, OBI-3424 as monotherapy demonstrated limited anti-leukemic activity in this difficult to treat population (nelarabine pre-treated and 20% post allogeneic transplant). OBI-3424 use in earlier lines of therapy or in synergistic combination regimens may be warranted.

Anjali Sunder Advani, MD: Incyte - Research Funding; Servier - Research Funding; Amgen - Research Funding; Pfizer - Research Funding; Seattle Genetics - Research Funding; Kura - Research Funding; Abbvie - Research Funding; Novartis - Research Funding; Immunogen - Research Funding; Kite - Research Funding; BEAM - Research Funding; OBI - Research Funding; Servier - Consultancy (Includes expert testimony); Syndax - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); Amgen - Consultancy (Includes expert testimony); Kite - Consultancy (Includes expert testimony); Astrazeneca - Consultancy (Includes expert testimony); Takeda - Consultancy (Includes expert testimony)